Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ennan Gu

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Contemporary Clinical Trials|January 23, 2021
Bayesian decision making in confirmatory early-stage breast cancer trialEnnan Gu, Xuan Zhou, Jing Zhao
Statistics in Medicine|July 29, 2020
Semiparametric estimation of the cure fraction in population-based cancer survival analysisEnnan Gu, Jiajia Zhang, Wenbin Lu, et al.
Journal of Biopharmaceutical Statistics|August 28, 2019
Estimation on conditional restricted mean survival time with counting processJunshan Qiu, Ennan Gu, Dali Zhou, et al.
Future Oncology (London, England)|October 10, 2024
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trialEhab L Atallah, Michael J Mauro, Koji Sasaki, et al.
Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Contemporary Clinical Trials|January 23, 2021
Bayesian decision making in confirmatory early-stage breast cancer trialEnnan Gu, Xuan Zhou, Jing Zhao
Statistics in Medicine|July 29, 2020
Semiparametric estimation of the cure fraction in population-based cancer survival analysisEnnan Gu, Jiajia Zhang, Wenbin Lu, et al.
Journal of Biopharmaceutical Statistics|August 28, 2019
Estimation on conditional restricted mean survival time with counting processJunshan Qiu, Ennan Gu, Dali Zhou, et al.
Future Oncology (London, England)|October 10, 2024
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trialEhab L Atallah, Michael J Mauro, Koji Sasaki, et al.
Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.
Pageof 1